[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-326920-105":59,"doc-detail-326920-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-the-oxytocin-receptor-for-breast-cancer-management-a-niche-for-peptide-tracers","Targeting the Oxytocin Receptor for Breast Cancer Management - A Niche for Peptide Tracers","","Breast cancer is a leading cause of death in women, and effective management depends on early diagnosis and ongoing monitoring, which remain difficult due to tumor heterogeneity and limited predictive biomarkers. This Perspective outlines diagnostic approaches, molecular receptor-targeting strategies, and the theranostic promise of the oxytocin receptor (OTR) in breast cancer. It reviews development of OTR-specific peptide tracers, including optical and nuclear agents, and discusses enabling chemistry and pharmacology, preclinical in vitro and in vivo results, key challenges, and future directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-oxytocin-receptor-for-breast-cancer-management-a-niche-for-peptide-tracers/326920/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-oxytocin-receptor-for-breast-cancer-management-a-niche-for-peptide-tracers/326920.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early diagnosis and monitoring challenging in breast cancer management?","Question",{"text":112,"@type":113},"Breast cancer’s heterogeneity and the scarcity of specific biomarkers make it hard to predict therapy responses and support personalized treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the significance of targeting receptors overexpressed in tumors?",{"text":117,"@type":113},"Receptors that are overexpressed in tumors but not in healthy cells provide promising targets for theranostics, enabling both study and potential treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"What role do OTR-specific optical and nuclear peptide tracers play?",{"text":121,"@type":113},"OTR tracers are developed to validate the oxytocin receptor’s role and theranostic potential, while supporting tumor visualization and aiming for more effective, safer, personalized treatment options.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},326920,1790095563,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","This article is licensed under CC-BY 4.0   \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Perspective   \nTargeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers  \nPredrag Kalaba,\\# Cristina Sanchez de la Rosa,\\# Andreas Möller, Paul F. Alewood, and Markus Muttenthaler *  \n Cite This: J. Med. Chem. 2024, 67, 1625−1640  \nRead Online  \n\n|  |  |  |  |\n| --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |\n\nABSTRACT: Breast cancer is a leading cause of death in women, and its management highly depends on early disease diagnosis and monitoring. This remains challenging due to breast cancer’s heterogeneity and a scarcity of specific biomarkers that could predict responses to therapy and enable personalized treatment. This Perspective describes the diagnostic landscape for breast cancer management, molecular strategies targeting receptors overexpressed in tumors, the theranostic potential of the oxytocin receptor (OTR) as an emerging breast cancer target, and the development of OTRspecific optical and nuclear tracers to study, visualize, and treat tumors. A special focus is on the chemistry and pharmacology underpinning OTR tracer development, preclinical in vitro and in vivo studies, challenges, and future directions. The use of peptide-based tracers targeting upregulated receptors in cancer is a highly promising strategy complementing current diagnostics and therapies and providing new opportunities to improve cancer management and patient survival.  \n■ SIGNIFICANCE  \nReceptors overexpressed in tumors but not healthy cells are promising targets for theranostics. The peptide hormone oxytocin receptor (OTR) is one such emerging target in breast cancer. Peptide-based optical and nuclear tracers are being developed that target OTR in breast cancer to validate OTR’s role and theranostic potential in breast cancer as well as to develop more effective, safer, and more personalized treatment options.  \n1. BREAST CANCER􀀁A HETEROGENEOUS DISEASE  \nBreast cancer is the second most common type of cancer diagnosed in women after non-melanoma skin cancers.1 The global cancer statistics reported 2.3 million newly diagnosed breast cancer cases and 684,996 deaths (responsible for 15.5% of total mortalities in females) in 2020.2,3 Despite having a favorable prognosis,4 breast cancer remains the leading cause of death in women worldwide.2 Efficient diagnosis and classification of breast cancer subtypes facilitate the management of the disease, but the heterogeneity of the malignant cells present in the mammary epithelial tissue often hinders accurate diagnosis.5 Current breast cancer diagnosis relies primarily on the assessment of molecular markers, such as the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2),6 and Ki67, a cancer antigen used as a marker for cell proliferation and now  \nan accepted prognostic factor to differentiate between ERpositive (ER+) tumor subtypes (Figure 1).7,8 Based on the expression of hormonal receptors, breast tumors can be classified into the following four subtypes: luminal A, luminal B, HER2-positive (HER2+), and triple-negative breast cancer (NBC).9 Luminal A tumors have the highest incidence  \n( 50%) among women but also have the best therapeutic ocome; by contrast, luminal B tumors have a lower incidence ( 15%) but worse prognosis.9 ER-negative∼ (ER− ) breast  \ntumors overexpressing HER2 (incidence of 20%) initially had poor therapy outcomes,9 which have improved in recent years due to the introduction of combination therapies.10 FDA-approved anti-HER2 agents include monoclonal antibodies Pertuzumab, Trastuzumab, and Ado-Trastuzumabemtansine (T-DM1);11 tyrosine kinase inhibitors Lapatinib (TYKERB), 11, 12 Neratinib (Nerlynx),12 and Tucatinib (Tukysa); 12 and the antibody−drug conjugate fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd, ENHERTU).13 Finally, tumors that are negative for the biomarkers mentioned ab","cbCairzH9BwfsN1q","https://ap.wps.com/l/cbCairzH9BwfsN1q","pdf",5753719,16,"English","# Abstract\n# Significance\n# Breast cancer: a heterogeneous disease\n## Molecular markers and subtype classification\n## Therapeutic implications and survival patterns\n# Oxytocin receptor and peptide tracer strategy","[{\"question\":\"Why is early diagnosis and monitoring challenging in breast cancer management?\",\"answer\":\"Breast cancer’s heterogeneity and the scarcity of specific biomarkers make it hard to predict therapy responses and support personalized treatment.\"},{\"question\":\"What is the significance of targeting receptors overexpressed in tumors?\",\"answer\":\"Receptors that are overexpressed in tumors but not in healthy cells provide promising targets for theranostics, enabling both study and potential treatment.\"},{\"question\":\"What role do OTR-specific optical and nuclear peptide tracers play?\",\"answer\":\"OTR tracers are developed to validate the oxytocin receptor’s role and theranostic potential, while supporting tumor visualization and aiming for more effective, safer, personalized treatment options.\"}]","Targeting the Oxytocin Receptor for Breast Cancer Management - A Niche for Peptide Tracers | PDF",1789975761]